News tagged with avastin
Avastin disappoints against ovarian cancer
Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer, too. Two studies found it did not improve survival for most of these patients and kept their ...
Cancer
Dec 28, 2011 |
4.3 / 5 (4) |
1
Studies: Avastin may fight early breast cancers
Surprising results from two new studies may reopen debate about the value of Avastin for breast cancer. The drug helped make tumors disappear in certain women with early-stage disease, researchers found.
Cancer
Jan 25, 2012 |
5 / 5 (2) |
0
Novel monoclonal antibody inhibits tumor growth in breast cancer and angiosarcoma
A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.
Cancer
Apr 19, 2013 |
5 / 5 (2) |
0
|
FDA approves Regeneron's eye injection Eylea
(AP) -- Regulators on Friday approved Regeneron Pharmaceuticals Inc.'s drug Eylea, an injection designed to treat a common cause of blindness in older people.
Medications
Nov 19, 2011 |
5 / 5 (1) |
5
Avastin, Sutent increase breast cancer stem cells, study shows
Cancer treatments designed to block the growth of blood vessels were found to increase the number of cancer stem cells in breast tumors in mice, suggesting a possible explanation for why these drugs don't ...
Cancer
Jan 25, 2012 |
5 / 5 (1) |
1
|
Counterfeit drugs becoming big business worldwide
(AP) -- The discovery that a fake version of the widely used cancer medicine Avastin is circulating in the United States is raising new fears that the multibillion-dollar drug-counterfeiting trade is increasingly ...
Medications
Feb 16, 2012 |
5 / 5 (1) |
1
System to catch fake drugs has idled for years
(AP) -- The news this week that a fake version of the cancer medicine Avastin has made its way into the United States highlights a longtime concern: There are few safeguards to make sure fake drugs can be ...
Medications
Feb 16, 2012 |
5 / 5 (1) |
0
Fake Avastin contained several chemicals, no drug
(AP) -- Counterfeit versions of the popular cancer drug Avastin obtained by European regulators contain a variety of chemicals, but not the active ingredient found in the genuine drug, according to drugmaker Roche.
Medications
Feb 28, 2012 |
5 / 5 (1) |
0
US warns of new fake batch of cancer drug Avastin
The Food and Drug Administration is warning U.S. doctors about another counterfeit version of the cancer drug Avastin, the third case involving the best-selling Roche drug in the past year.
Medications
Feb 06, 2013 |
5 / 5 (1) |
0
Novartis tries to make UK hospitals use $1000 drug
(AP) -- Drug maker Novartis says it is taking legal action in Britain to make hospitals use an eye drug that costs 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).
Medications
Apr 24, 2012 |
1 / 5 (1) |
0
Bevacizumab
Bevacizumab (trade name Avastin, Genentech/Roche) is a monoclonal antibody that recognises all vascular endothelial growth factor (VEGF) isoforms. It is used in the treatment of cancer, where it inhibits tumor growth by blocking the formation of new blood vessels (angiogenesis). Bevacizumab was the first clinically available angiogenesis inhibitor in the United States.
Bevacizumab is currently approved by the U.S. Food and Drug Administration (FDA) for cancers that are metastatic (have spread to other parts of the body). It received its first approval in 2004 was for combination use with standard chemotherapy for metastatic colon cancer and non-small cell lung cancer. In 2008, it was approved by the FDA for use in metastatic breast cancer, a decision that generated some controversy as it went against the recommendation of its advisory panel, who objected because it only slowed tumor growth but failed to extend survival.
Clinical studies are underway in non-metastatic breast cancer, renal cell carcinoma, glioblastoma multiforme, ovarian cancer, castrate-resistant (formally called hormone refractory) prostate cancer, non-metastatic unresectable liver cancer and metastatic or unresectable locally advanced pancreatic cancer. A study released in April 2009 found that bevacizumab is not effective at preventing recurrences of non-metastatic colon cancer following surgery. In May 2009, it received FDA approval for treatment of reoccurring Glioblastoma Multiforme, while treatment for initial growth is still in phase III clinical trial.
For more information about Bevacizumab, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
